Dual inhibition of the TrkA and JAK2 pathways using entrectinib and pacritinib suppresses the growth and metastasis of HER2-positive and triple-negative breast cancers-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Dual inhibition of the TrkA and JAK2 pathways using entrectinib and pacritinib suppresses the growth and metastasis of HER2-positive and triple-negative breast cancers

Published:2024-08 Issue: Volume:597 Page:217023
ISSN:0304-3835
Container-title:Cancer Letters
language:en
Short-container-title:Cancer Letters

Author:

Regua Angelina T.,Bindal Shivani^ORCID,Najjar Mariana K.^ORCID,Zhuang Chuling^ORCID,Khan Munazza^ORCID,Arrigo Austin B.J.^ORCID,Gonzalez Anneliese O.,Zhang Xinhai R.^ORCID,Zhu Jay-Jiguang^ORCID,Watabe Kounosuke,Lo Hui-Wen^ORCID

Funder

National Institutes of Health

US Department of Defense

American Association for Cancer Research

METAvivor

Publisher

Elsevier BV

Reference50 articles.

1. Cancer statistics;Siegel;CA A Cancer J. Clin.,2022

2. Howlader N, Noone AM, Krapcho M, Miller D, Brest A, Yu M, et al. SEER Cancer Statistics Review, 1975-2016, National Cancer Institute. Bethesda, MD, https://seer.cancer.gov/csr/1975_2016/, based on November 2018 SEER data submission, posted to the SEER web site, April 2019.

3. Molecular portraits of human breast tumours;Perou;Nature,2000

4. Breast cancer treatment: a review;Waks;JAMA,2019

5. Molecular subtype predicts incidence and prognosis of brain metastasis from breast cancer in SEER database;Kim;J. Cancer Res. Clin. Oncol.,2018

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP